Sun Pharma Sets New Milestone in Cancer Treatment with FDA Label Enhancement

Sun Pharmaceutical Industries Limited , through its acquisition of Checkpoint Therapeutics’ assets, has secured an important label update approval from the US Food and Drug Administration (FDA) for its immuno-oncology drug Unloxcyt (cosibelimab-ipdl). Unloxcyt is the first and only anti-PD-L1 antibody approved for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC), a severe skin cancer subtype with limited treatment options.

The FDA label update reflects new clinical insights and revised prescribing information enhancing the safe and effective use of Unloxcyt in adults who cannot undergo curative surgery or radiation therapy. The drug works by blocking PD-L1, a protein that tumors use to evade immune attack, thereby reinvigorating the patient’s immune response against cancer cells.

This update is part of Sun Pharma’s strategy to expand its innovative oncology portfolio and bring differentiated immunotherapy options to patients worldwide. With this label enhancement, Unloxcyt may offer more personalized treatment approaches and improved patient outcomes.

Key highlights:

FDA approves updated labeling for Unloxcyt (cosibelimab-ipdl) in advanced cSCC treatment

Unloxcyt is the first anti-PD-L1 therapy approved for metastatic/locally advanced cSCC

Recommended for patients not suitable for curative surgery or radiation

Drug mechanism targets immune evasion by tumor cells via PD-L1 blockade

Label update improves clinical guidance for physicians on use and safety

Strengthens Sun Pharma’s oncology presence with innovative immunotherapy

Result of Sun Pharma’s acquisition of Checkpoint Therapeutics and its assets

Sources: FDA official releases, Sun Pharmaceutical Industries Limited, Checkpoint Therapeutics, Nasdaq, PharmaTech​